Galsulfase IV bulk supplier for pharma manufacturers

Galsulfase Iv 1mg/ml Suppliers & Bulk Manufacturers

Available Forms: Lyophilized powder for IV

Available Strengths: 1mg/ml

Reference Brands: Vimizim®(US & EU)

Galsulfase is an enzyme replacement therapy that provides the deficient N-acetylgalactosamine-6-sulfatase enzyme in Morquio A syndrome. It reduces the buildup of glycosaminoglycans in the body, improving mobility, breathing, and overall functioning, leading to enhanced quality of life in affected patients.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Galsulfase, marketed as Vimizim®, is approved in the US and EU for mucopolysaccharidosis type IVA (Morquio A syndrome). Regulatory dossiers include comprehensive clinical trial data, manufacturing practices, and safety profiles submitted to FDA and EMA, supporting its approval. Dossiers demonstrate its efficacy in reducing symptoms and improving mobility. Administered via IV infusion, dosing is individualized according to patient weight. For in-depth insights on regulatory submissions, dossier requirements, and market approvals, visit PharmaTradz, your trusted source for pharmaceutical regulatory updates and industry insights.

Galsulfase Iv — third party manufacturing & bulk supply

Galsulfase Iv 1mg/ml is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Galsulfase Iv is supplied as Lyophilized powder for IV — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Galsulfase Iv listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Galsulfase Iv →

Back to Listing

Frequently Asked Questions

Galsulfase IV is listed as Lyophilized powder for IV in 1mg/ml. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Galsulfase IV is referenced against Vimizim®(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.